quotes and stock data delayed 15 minutes
Burn Rate (Qtr)
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH).
Click on drug name or indication to see upcoming trial info, prior data, and more general information
Drug | Disease (links)
Stage (next event)
See what the community is saying - click to see full post